Small-molecule Ro-08-2750 interacts with many RNA-binding proteins and elicits MUSASHI2-independent phenotypes
- Kathryn Walters1,2,
- Marcin Piotr Sajek1,2,3,
- Elisabeth Murphy1,2,
- Aaron Issaian1,
- Amber Baldwin1,2,
- Evan Harrison1,2,
- Miles Daniels1,2,4,
- Julie A. Reisz1,
- Kirk Hansen1,
- Angelo D'Alessandro1 and
- Neelanjan Mukherjee1,2
- 1Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
- 2RNA Bioscience Initiative, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
- 3Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland
- 4Howard University Karsh STEM Scholars Program, Washington DC 20059, USA
- Corresponding author: neelanjan.mukherjee{at}cuanschutz.edu
Abstract
RNA-binding proteins (RBPs) are key regulators of gene expression. Small molecules targeting these RBP–RNA interactions are a rapidly emerging class of therapeutics for treating a variety of diseases. Ro-08-2750 (Ro) is a small molecule identified as a competitive inhibitor of Musashi (MSI)–RNA interactions. Here, we show that multiple Ro-dependent cellular phenotypes, specifically adrenocortical steroid production and cell viability, are Musashi-2 (MSI2)-independent. Using an unbiased proteome-wide approach, we discovered Ro broadly interacts with RBPs, many containing RRM domains. To confirm this finding, we leveraged the large-scale ENCODE data to identify a subset of RBPs whose depletion phenocopies Ro inhibition, indicating Ro is a promiscuous inhibitor of multiple RBPs. Consistent with broad disruption of ribonucleoprotein complexes, Ro treatment leads to stress granule formation. This strategy represents a generalizable framework for validating the specificity and identifying targets of RBP inhibitors in a cellular context.
Keywords
- Received January 20, 2023.
- Accepted June 13, 2023.
This article, published in RNA, is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.










